Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease

被引:81
作者
Harrington, KA
Augood, SJ
Kingsbury, AE
Foster, OJF
Emson, PC
机构
[1] BABRAHAM INST,DEPT NEUROBIOL,MRC,MOL NEUROSCI GRP,CAMBRIDGE CB2 4AT,ENGLAND
[2] PARKINSONS DIS SOC,BRAIN BANK,LONDON,ENGLAND
来源
MOLECULAR BRAIN RESEARCH | 1996年 / 36卷 / 01期
关键词
dopamine transporter; synaptic vesicle amine transporter; in situ hybridization; neuromelanin; Parkinson's disease;
D O I
10.1016/0169-328X(95)00278-Z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The cellular expression of DAT mRNA and VMAT2 mRNA was investigated in sections of the human post-mortem substantia nigra in control and Parkinson's disease tissue using in situ hybridisation techniques. Short synthetic oligodeoxynucleotides were used to detect these gene transcripts at the cellular level. In the control human nigra, high levels of expression were seen in all sub-divisions of the substantia nigra, especially within medial regions. By contrast, the level of expression of both DAT mRNA and VMAT2 mRNA was markedly reduced in Parkinson's disease; these reductions in hybridisation signal were associated with (i) a marked loss of dopamine-containing cells in the substantia nigra, and (ii) a reduction in both DAT and VMAT2 signal per cell in the remaining pigmented neurones. These disease-related decreases in the cellular abundance of both DAT and VMAT2 gene transcripts in the surviving cells of the parkinsonian nigra may reflect compensatory changes in catecholamine signalling or may be a consequence of neuronal dysfunction.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 29 条
[1]   DOPAMINE UPTAKE SITES IN PARKINSONS-DISEASE AND IN DEMENTIA OF THE ALZHEIMER-TYPE [J].
ALLARD, PO ;
RINNE, J ;
MARCUSSON, JO .
BRAIN RESEARCH, 1994, 637 (1-2) :262-266
[2]   COEXPRESSION OF DOPAMINE TRANSPORTER MESSENGER-RNA AND TYROSINE-HYDROXYLASE MESSENGER-RNA IN VENTRAL MESENCEPHALIC NEURONS [J].
AUGOOD, SJ ;
WESTMORE, K ;
MCKENNA, PJ ;
EMSON, PC .
MOLECULAR BRAIN RESEARCH, 1993, 20 (04) :328-334
[3]  
AUGOOD SJ, 1995, J NEUROSCI, V15, P865
[4]  
AXELROD JULIUS, 1965, RECENT PROG HORMONE RES, V21, P597
[5]   [H-3] SPIPERONE BINDING, DOPAMINE AND HVA CONCENTRATIONS IN PARKINSONS-DISEASE AND SUPRANUCLEAR PALSY [J].
BOKOBZA, B ;
RUBERG, M ;
SCATTON, B ;
JAVOYAGID, F ;
AGID, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 99 (2-3) :167-175
[6]   A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE [J].
BURNS, RS ;
CHIUEH, CC ;
MARKEY, SP ;
EBERT, MH ;
JACOBOWITZ, DM ;
KOPIN, IJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14) :4546-4550
[7]  
Cohen G, 1983, J Neural Transm Suppl, V19, P89
[8]  
COHEN G, 1990, J NEURAL TRANSM-SUPP, V32, P229
[9]   MIDBRAIN DOPAMINERGIC CELL LOSS IN PARKINSONS-DISEASE AND MPTP-INDUCED PARKINSONISM - SPARING OF CALBINDIN-D(28K)-CONTAINING CELLS [J].
GERMAN, DC ;
MANAYE, KF ;
SONSALLA, PK ;
BROOKS, BA .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1992, 648 :42-62
[10]  
GIROS B, 1992, MOL PHARMACOL, V42, P383